SHAREHOLDER INVESTOR REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics

Core Viewpoint - Tvardi Therapeutics, Inc. experienced a significant decline in stock value, dropping over 80% following disappointing preliminary data from its Phase 2 REVERT clinical trial for TTI-101 in idiopathic pulmonary fibrosis [5]. Group 1: Company Overview - Tvardi Therapeutics, Inc. is a publicly traded company listed on NASDAQ under the ticker TVRD [4]. - The company is currently under investigation by Faruqi & Faruqi, LLP, a national securities law firm, for potential claims related to the significant losses suffered by investors [4]. Group 2: Clinical Trial Results - The Phase 2 REVERT clinical trial aimed to evaluate the safety, pharmacokinetics, and exploratory outcomes related to lung function of TTI-101 [5]. - Preliminary data indicated that the trial did not meet its goals, with changes in Forced Vital Capacity (FVC) not showing the expected efficacy [5]. - The baseline characteristics of patients were similar across treatment arms, except for a lower percent predicted FVC in the placebo group compared to those treated with TTI-101 [5].